WE’RE IN THIS TOGETHER
I am Stuart Henderson and I am the global managing director of our Life Sciences practice here at Accenture.

I can't think of a more exciting time to have this role. The life sciences industry is in what I believe will be its finest and most exciting era.

A time where new science is addressing unmet needs in entirely new ways and combining with new technology to solve some of the most challenging diseases.

One of the most exciting areas is oncology.

We expect to see more than 300 new treatments come to market in oncology by 2023.

What was once considered a death sentence will increasingly become a chronic disease -- for even the most devastating types.

I am already the personal beneficiary of this. My brother has had cancer twice and is on the road to recovery after a CNS T-Cell Lymphoma.

So when I say we are in this together, I really mean we are in this together.

We all have people we love who have faced or are facing a significant health challenge.

We are entering a time where we can surround patients with the care they need ALL THE TIME – shifting care from being episodic to always on --“24/7”-- and increasingly moving to lower cost care settings, including at home.

Treating them where they are, integrating with their lives.
And better yet, intercepting disease before it even happens.
For example, blood biopsies have the potential to spot cancer earlier and become a part of routine screening.

We are seeing very exciting new business models emerging that are on the case already.

So life sciences companies have a tremendous opportunity ahead of them.

An opportunity to transform and grow their current business models while building new ones.
….to drive exceptional growth through new science.
….to use data, analytics, machine learning and AI to understand science and patients in new ways.
….to connect across the healthcare system to surround patients with the care they need, when and where they need it.

This will take courage, the courage to pivot out of the comfort zone of the core life sciences business and to build innovative models that this new environment demands.

But, we are in this together and together this industry will solve for patients’ greatest needs.